Boehringer Ingelheim and Click Therapeutics have revealed the data from their pivotal trial of digital therapeutic (DTx) CT-155 for schizophrenia, which has shown efficacy against some of the symptoms that are hardest to address with drug therapies.

Schizophrenia is a chronic psychiatric disorder that requires lifelong management, with consistent medication adherence essential to prevent relapse and disability. Counseling that emphasizes empathy, trust, and shared decision-making helps patients ...

Ashley Smith says treatment and hope are the keys to her journey—carrying her from her darkest days to a brighter tomorrow.